Sign in
OLMA Stock Price, Chart, Stats & News
Olema Pharmaceuticals, Inc.
Save
919.77M
Market cap
–
Current P/E
–
Forward P/E
OLMA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -30.45% |
ROE | -42.90% |
D/E | 0.00x |
Interest coverage ratio | – |
OLMA valuation
P/E | – |
P/S | – |
P/B | 2.61x |
P/CF | -8.51x |
P/FCF | -8.12x |
P/OCF | -8.51x |
PEG | -2.12x |
EV multiple | -7.10x |
About
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations.
Similar securities
Based on sector and market capitalization
Report issue